ATRIDOX (doxycycline hyclate) by Pfizer is tetracyclines are readily absorbed and are bound to plasma proteins in varying degree. Approved for acne vulgaris, gonorrhea, chlamydia and 2 more indications. First approved in 1998.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
ATRIDOX is a periodontal extended-release doxycycline hyclate system approved in 1998 for treatment of acne vulgaris, gonorrhea, chlamydia, syphilis, and other sexually transmitted infections. It works by inhibiting bacterial protein synthesis through binding to the 30S ribosomal subunit, providing bacteriostatic activity against a broad range of gram-positive and gram-negative bacteria. The drug is readily absorbed orally with peak serum levels at 2 hours and a half-life of 18-22 hours regardless of renal function.
Product is approaching loss of exclusivity with moderate competitive pressure (30%), indicating a mature asset with contracting commercial opportunity and likely smaller team size.
Tetracyclines are readily absorbed and are bound to plasma proteins in varying degree. They are concentrated by the liver in the bile, and excreted in the urine and feces at high concentrations and in a biologically active form. Doxycycline is virtually completely absorbed after oral…
Worked on ATRIDOX at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Double-blind-randomized,Placebo Controlled Trial for Chemotherapy-associated Oral Mucositis Using Doxycycline Hyclate
Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on ATRIDOX offers limited growth opportunity given LOE approach and zero linked job availability; career progression is best suited for professionals seeking managed-care or market-maintenance experience in a maturing asset. Roles focus on defending market share, optimizing pricing, and managing transition strategies rather than growth-phase innovation.